Circumventing qPCR inhibition to amplify miRNAs in plasma

Biomarker Research

Jordan L Plieskatt¹  Yanjun Feng¹  Gabriel Rinaldi¹  Jason P Mulvenna²  Jeffrey M Bethony¹  Paul J Brindley¹ 

[1] Department of Microbiology, Immunology and Tropical Medicine, and Research Center for the Neglected Diseases of Poverty, School of Medicine and Health Sciences, George Washington University, Washington, D.C., USA

[2] The University of Queensland, School of Biomedical Sciences, Brisbane, Queensland, Australia

关键词: Bacteroides heparinase I;    Eliminase;    Heparinase;    Heparin;    Anti-coagulant;    Biomarker;    qPCR;    Reverse transcriptase;    Plasma;    Interference;    miRNA;   

Others  :  1084175
DOI  :  10.1186/2050-7771-2-13

 received in 2014-03-24, accepted in 2014-07-11,  发布年份 2014

【 摘 要 】

Background

Circulating microRNAs (c-miRNAs) have be identified in saliva, urine and blood, which has led to increasing interest in their development as biomarkers for diverse diseases including cancers. One of the key advantages of c-miRNAs over other biomarkers is the ability to be amplified and quantified by quantitative PCR (qPCR). However, at phlebotomy when whole blood is dispensed into heparinized tubes, residual levels of the anti-coagulant lithium heparin may remain in the plasma and hence with RNA isolated from the plasma. This can confound the detection of c-miRNAs by qPCR because it inhibits reverse transcriptase (RT). Here we present a procedure, modified from earlier techniques, to detect c-miRNAs in plasma that improves sensitivity and streamlines performance.

Findings

Treatment of total RNA isolated from human blood plasma with Bacteroides heparinase I during reverse transcription at 37°C for one hour improved sensitivity and performance of the qPCR. This is in comparison to no treatment or treatment of the RNA prior to RT, which is the current suggested method and exposes plasma to Flavobacterium heparinum heparinase I for up to 2 hours before RT. This modest alteration improved qPCR performance and resulted in lowered threshold cycles (C_t) for detection of the target sequence, candidate c-miRNA biomarkers, and controls. It also reduced the expense and number of processing steps, shortening the duration of the assay and minimizing exposure of RNA to elevated temperatures.

Conclusion

Incorporating Bacteroides heparinase I treatment into conventional RT protocols targeting c-miRNA in plasma can be expected to expedite the discovery of biomarkers.

【 授权许可】

   
2014 Plieskatt et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Calin GA, Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer 2006, 6:857-866.
• [2]Sun W, Li YSJ, Huang HD, Shyy JYJ, Chien S: microRNA: A master regulator of cellular processes for bioengineering systems. Ann Rev Biomed Eng 2010, 12:1-27.
• [3]He L, Hannon GL: MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004, 5:522-531.
• [4]Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
• [5]Git A, Dvinge H, Salmon-Divon M, Osborne M, Kutter C, Hadfield J, Bertone B, Caldas C: Systematic comparison of microarray profiling, real-time PCR, and next-generation sequencing technologies for measuring differential microRNA expression. RNA 2010, 16:991-1006.
• [6]Pigati L, Yaddanapudi SC, Iyengar R, Kim DJ, Hearn SA, Danforth D, Hastings ML, Duelli DM: Selective release of microRNA species from normal and malignant mammary epithelial cells. PLoS One 2010, 5:e13515.
• [7]Pu XX, Huang GL, Guo HQ, Guo CC, Li H, Ye S, Ling S, Jiang L, Tian Y, Lin TY: Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression. J Gastroenterol Hepatol 2010, 25:1674-1680.
• [8]Resnick KE, Alder H, Hagan JP, Richardson DL, Croce CM, Cohn DE: The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol 2009, 112:55-59.
• [9]Mostert B, Sieuwerts AM, Martens JW, Sleijfer S: Diagnostic applications of cell-free and circulating tumor cell-associated miRNAs in cancer patients. Exp Rev Mol Diagn 2011, 11:259-275.
• [10]Ginzinger DG: Gene quantification using real-time quantitative PCR: an emerging technology hits the mainstream. Exp Hematol 2002, 30:503-512.
• [11]Siev M, Yu X, Prados_Rosales R, Martiniuk FT, Achkar JM: Correlation between serum and plasma antibody titers to mycobacterial antigens. Clin Vaccine Immunol 2011, 18:173-175.
• [12]Johnson ML, Navanukraw C, Grazul-Bilska AT, Reynolds LP, Redmer DA: Heparinase treatment of RNA before quantitative real-time RT-PCR. Bio Tech 2003, 35:1140-1142. 1144
• [13]Bai X, Fischer S, Keshavjee S, Liu M: Heparin interference with reverse transcriptase polymerase chain reaction of RNA extracted from lungs after ischemia-reperfusion. Transpl Int 2000, 13:146-150.
• [14]Garcia ME, Blanco JL, Caballero J, Gargallo-Viola D: Anticoagulants interfere with PCR used to diagnose invasive aspergillosis. J Clin Microbiol 2002, 40:1567-1568.
• [15]Sripa B, Brindley PJ, Mulvenna J, Laha T, Smout MJ, Mairiang E, Bethony JM, Loukas A: The tumorigenic liver fluke Opisthorchis viverrini -- multiple pathways to cancer. Trends Parasitol 2012, 28:395-407.
• [16]Lim LP, Lau NC, Weinstein EG, Abdelhakim A, Yekta S, Rhoades MW, Burge CB, Bartel DP: The microRNAs of Caenorhabditis elegans. Gen Dev 2003, 17:991-1008.
• [17]Plieskatt JL, Rinaldi G, Feng Y, Levine PH, Easley S, Martinez E, Hashmi S, Sadeghi N, Brindley PJ, Bethony JM, Mulvenna JP: Methods and matrices: approaches to identifying miRNAs for Nasopharyngeal carcinoma. J Trans Med 2014, 12:3. BioMed Central Full Text
• [18]Merchant ZM, Kim YS, Rice KG, Linhardt RJ: Structure of heparin-derived tetrasaccharides. Biochem J 1985, 229:369-377.
• [19]Yamada S, Murakami T, Tsuda H, Yoshida K, Sugahara K: Isolation of the porcine heparin tetrasaccharides with glucuronate 2-O-sulfate. Heparinase cleaves glucuronate 2-O-sulfate-containing disaccharides in highly sulfated blocks in heparin. J Biol Chem 1995, 270:8696-8705.
• [20]Plieskatt JL, Rinaldi G, Feng Y, Peng J, Yonglitthipagon P, Easley S, Laha T, Pairojkul C, Bhudhisawasdi V, Sripa B, Brindley PJ, Mulvenna JP, Bethony JM: Distinct miRNA signatures associate with subtypes of cholangiocarcinoma from infection with the tumorigenic liver fluke Opisthorchis viverrini. J Hepatol 2014. doi:10.1016/j.jhep.2014.05.035